AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27831635 — intervention group
Group type: EXPERIMENTAL
Intervention: Short GnRH agonist protocol
Number of subjects: 250
Study 27831635 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate plus FSH and antagonist
Number of subjects: 250
Study 27831635 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 250
Study 25335325 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangtang Xiaozhi Capsule (JTXZC), 4 pills three times per day for 8 weeks
Number of subjects: 73
Study 25335325 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone Tablet, 15 mg once daily for 8 weeks
Number of subjects: 73
Study 23184201 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic pacemaker placement
Number of subjects: 5
Study 20407035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses of vincristine and corticosteroids
Number of subjects: 411
Study 20407035 — intervention group
Group type: COMPARATOR
Intervention: No pulses
Number of subjects: 411
Study 20407035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses in PRED group
Number of subjects: 411
Study 20407035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses in DEX group
Number of subjects: 411
Study 20407035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses in girls
Number of subjects: 411
Study 20407035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses in boys
Number of subjects: 411
Study 20407035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses
Number of subjects: 411
Study 18199700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests for malaria
Number of subjects: 2425
Study 18199700 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 2425
Study 18199700 — intervention group
Group type: COMPARATOR
Intervention: Presumptive treatment
Number of subjects: 2425
Study 15928281 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated grief treatment
Number of subjects: 95
Study 15928281 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 95
Study 12869086 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (n=45)
Number of subjects: 90
Study 12869086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=45)
Number of subjects: 90
Study 8931917 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg, intravenously)
Number of subjects: 0
Study 8931917 — intervention group
Group type: COMPARATOR
Intervention: Saline-injected controls
Number of subjects: 0
Study 1673050 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 50 mg
Number of subjects: 48
Study 1673050 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 48
Study 1673050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7008800 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole 150 mg weekly
Number of subjects: 26
Study 7008800 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 30443778 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized virtual surgical planning (VSP)
Number of subjects: 21
Study 30443778 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical planning (CSP)
Number of subjects: 21
Study 28270226 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived mesenchymal stem cells (ASC) administered to the submandibular glands
Number of subjects: 30
Study 28270226 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to the submandibular glands
Number of subjects: 30
Study 28270226 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived mesenchymal stem cells (ASC)
Number of subjects: 30
Study 28270226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26451726 — intervention group
Group type: EXPERIMENTAL
Intervention: FloraGLO® (Kemin Japan)
Number of subjects: 36
Study 26451726 — intervention group
Group type: EXPERIMENTAL
Intervention: XanMax® (Katra Phytochem)
Number of subjects: 36
Study 26451726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplement groups
Number of subjects: 36
Study 23786610 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 M EDC
Number of subjects: 6
Study 23786610 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 M EDC
Number of subjects: 6
Study 23786610 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 M EDC + 35% HEMA
Number of subjects: 6
Study 23786610 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PA
Number of subjects: 6
Study 23786610 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX
Number of subjects: 6
Study 23786610 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (control)
Number of subjects: 6
Study 21930310 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary postoperative intervention program
Number of subjects: 64
Study 21930310 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative routines
Number of subjects: 64
Study 19207345 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive MI/CBT
Number of subjects: 97
Study 19207345 — intervention group
Group type: COMPARATOR
Intervention: BI alone
Number of subjects: 97
Study 19207345 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-based treatment
Number of subjects: 97
Study 17987226 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV L1 VLP vaccines
Number of subjects: 0
Study 15293422 — intervention group
Group type: EXPERIMENTAL
Intervention: SingleBond + Filtek Z250 (SB)
Number of subjects: 4
Study 15293422 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond + AP-X (SE)
Number of subjects: 4
Study 12772885 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, plus a 5‐day continuous infusion of 750 mg/m2 5‐fluorouracil (FU; TCF)
Number of subjects: 158
Study 12772885 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 85 mg/m2 plus cisplatin 75 mg/m2 (TC)
Number of subjects: 158
Study 9850487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment policy with sulfonylurea
Number of subjects: 0
Study 9850487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment policy with metformin
Number of subjects: 0
Study 9850487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment policy with insulin
Number of subjects: 0
Study 9850487 — intervention group
Group type: COMPARATOR
Intervention: Conventional policy (diet therapy)
Number of subjects: 0
Study 8602338 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing dentifrice (0.3% triclosan, 2% Gantrez copolymer, 0.243% sodium fluoride)
Number of subjects: 325
Study 8602338 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice without triclosan
Number of subjects: 325
Study 2665109 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care group
Number of subjects: 87
Study 2665109 — intervention group
Group type: COMPARATOR
Intervention: GP-control group
Number of subjects: 87
Study 338105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, 1 g daily, as a continuous infusion into the portal venous system during the first seven days after operation.
Number of subjects: 50
Study 338105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 50
Study 31510957 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community case management (iCCM) by community health volunteers (CHVs) trained to screen, diagnose, and treat MAM and SAM.
Number of subjects: 240
Study 31510957 — intervention group
Group type: COMPARATOR
Intervention: Control arm with CHVs only screening and referring MAM/SAM cases to health facilities.
Number of subjects: 240
Study 26369302 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team intervention
Number of subjects: 4
Study 26369302 — intervention group
Group type: COMPARATOR
Intervention: Regular ad hoc organization (control)
Number of subjects: 4
Study 26218029 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable prostheses
Number of subjects: 10
Study 26218029 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported fixed prostheses
Number of subjects: 10
Study 26218029 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects with Class I natural dentition)
Number of subjects: 10
Study 23936607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 106
Study 21524765 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg/bid for 8 weeks
Number of subjects: 38
Study 18056769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical oral contraception (21‐d active/7‐d placebo for six consecutive 28‐d cycles)
Number of subjects: 62
Study 18056769 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral contraception (168‐d active pill)
Number of subjects: 62
Study 17153971 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide 10%, 15%, or 20%
Number of subjects: 44
Study 12698777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydration (2L of water daily)
Number of subjects: 30
Study 12698777 — intervention group
Group type: COMPARATOR
Intervention: Control group (AFI > 10th and < 90th percentile)
Number of subjects: 30
Study 11200750 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochromatographic assay detecting IgG antibodies against antigen 38 kDa (Rapid Test TB)
Number of subjects: 278
Study 8999567 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation ad modum Hoffman
Number of subjects: 41
Study 8999567 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous pinning and plaster cast
Number of subjects: 41
Study 1281729 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (2, 5 or 10 mg)
Number of subjects: 137
Study 1281729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 6373442 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg b.i.d.
Number of subjects: 93
Study 6373442 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 25 mg b.i.d.
Number of subjects: 93
Study 6373442 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 50 mg b.i.d.
Number of subjects: 93
Study 31343273 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial micronutrients (n=19)
Number of subjects: 93
Study 31343273 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric medications (n=21)
Number of subjects: 93
Study 31343273 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=35)
Number of subjects: 93
Study 31343273 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial micronutrients
Number of subjects: 93
Study 28320323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium administered with closed-loop feedback infusion system in group laparoscopy
Number of subjects: 60
Study 28320323 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium administered with closed-loop feedback infusion system in group control
Number of subjects: 60
Study 28320323 — intervention group
Group type: COMPARATOR
Intervention: Group laparoscopy compared to group control
Number of subjects: 60
Study 28320323 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 60
Study 26773906 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran ER (40-120mg/d)
Number of subjects: 2666
Study 24634065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered in groups
Number of subjects: 0
Study 24634065 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 0
Study 22473809 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g curcumin
Number of subjects: 36
Study 22473809 — intervention group
Group type: COMPARATOR
Intervention: 4g placebo
Number of subjects: 36
Study 22473809 — intervention group
Group type: EXPERIMENTAL
Intervention: 8g curcumin (open-label extension)
Number of subjects: 36
Study 19765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (125 mg)
Number of subjects: 2419
Study 19765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine (250 mg) plus pyrimethamine (12.5 mg)
Number of subjects: 2419
Study 19765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil (15 mg) plus dapsone (18.75 mg)
Number of subjects: 2419
Study 19765815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2419
Study 19765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 2419
Study 19765815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 2419
Study 17188097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) curriculum
Number of subjects: 20
Study 17188097 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum (Control)
Number of subjects: 20
Study 15492301 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 supervised sessions per week for 4 months)
Number of subjects: 28
Study 15492301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alteration in normal activity levels)
Number of subjects: 28
Study 11208630 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled albuterol (100 microg per puff, in 2 puffs four times daily)
Number of subjects: 53
Study 9565263 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implants connected by a Dolderbar
Number of subjects: 0
Study 9565263 — intervention group
Group type: COMPARATOR
Intervention: Transmandibular implant (TMI)
Number of subjects: 0
Study 8139479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, low-cholesterol diet (LFD)
Number of subjects: 19
Study 8139479 — intervention group
Group type: COMPARATOR
Intervention: Higher-fat, higher-cholesterol diet (HFD)
Number of subjects: 19
Study 3421513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (0.05 and 0.10 mg/kg)
Number of subjects: 24
Study 3421513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol (50 and 100 mg)
Number of subjects: 24
Study 3421513 — intervention group
Group type: COMPARATOR
Intervention: Control period (no atenolol)
Number of subjects: 24
Study 28500743 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 505
Study 28500743 — intervention group
Group type: COMPARATOR
Intervention: ProGlide
Number of subjects: 505
Study 26764872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 320
Study 26764872 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 320
Study 26764872 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 320
Study 25588408 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality Orientation (RO) sessions for 6 months
Number of subjects: 14
Study 25588408 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with donepezil only)
Number of subjects: 14
Study 23084002 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism manipulation
Number of subjects: 79
Study 23084002 — intervention group
Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 79
Study 21180675 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (CH) containing 1% chloramine-T
Number of subjects: 30
Study 21180675 — intervention group
Group type: COMPARATOR
Intervention: Commercial-brand dentifrice (TR) containing triclosan
Number of subjects: 30
Study 17318860 — intervention group
Group type: EXPERIMENTAL
Intervention: New adjuvanted hepatitis B vaccine
Number of subjects: 16
Study 17318860 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaccine (booster)
Number of subjects: 16
Study 15100697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 52
Study 15100697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11350019 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 11350019 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 0
Study 11350019 — intervention group
Group type: COMPARATOR
Intervention: Sweat pyridinoline
Number of subjects: 0
Study 11350019 — intervention group
Group type: COMPARATOR
Intervention: First morning void urine pyridinoline
Number of subjects: 0
Study 11350019 — intervention group
Group type: COMPARATOR
Intervention: 24-hour urine pyridinoline
Number of subjects: 0
Study 9680894 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg per day)
Number of subjects: 409
Study 9680894 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg per day)
Number of subjects: 409
Study 9680894 — intervention group
Group type: EXPERIMENTAL
Intervention: both alpha-tocopherol and beta-carotene
Number of subjects: 409
Study 9680894 — intervention group
Group type: COMPARATOR
Intervention: placebo capsules
Number of subjects: 409
Study 7976797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 4 mg
Number of subjects: 12
Study 7976797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 8 mg
Number of subjects: 12
Study 7976797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3069767 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBY)
Number of subjects: 51
Study 3069767 — intervention group
Group type: COMPARATOR
Intervention: Gastroplasty (GPL)
Number of subjects: 51
Study 4218236 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular enzyme from Myxobacter AL-1
Number of subjects: 0
Study 4218236 — intervention group
Group type: COMPARATOR
Intervention: Chitosan
Number of subjects: 0
Study 30086213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/d
Number of subjects: 209
Study 30086213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 28150423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetyl hexapeptide‐3 with tripeptide‐10 citrulline (Group G1)
Number of subjects: 24
Study 28150423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripeptide‐10 citrulline (Group G2)
Number of subjects: 24
Study 28150423 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl hexapeptide‐3 (Group G3)
Number of subjects: 24
Study 24042339 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral training
Number of subjects: 2
Study 24042339 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial training
Number of subjects: 2
Study 23904619 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h spatial learning task in humans
Number of subjects: 0
Study 23904619 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 d training in a Morris water maze in rats
Number of subjects: 0
Study 21921843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol (doxorubicin 30 mg/m plus cisplatin 100 mg/m with lipiodol emulsification)
Number of subjects: 71
Study 21921843 — intervention group
Group type: COMPARATOR
Intervention: Solution (doxorubicin 30 mg/m plus cisplatin 100 mg/m without lipiodol emulsification)
Number of subjects: 71
Study 21921843 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (both groups combined)
Number of subjects: 71
Study 21921843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (both groups combined)
Number of subjects: 71
Study 18701822 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial clear sealant
Number of subjects: 166
Study 18701822 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque sealants
Number of subjects: 166
Study 18701822 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nanofilled clear sealant
Number of subjects: 166
Study 16881976 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHER sirolimus‐eluting stent
Number of subjects: 25
Study 14695863 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 300,000 units of vitamin D(2)
Number of subjects: 150
Study 14695863 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected vitamin D(2) plus 1 g/day oral calcium
Number of subjects: 150
Study 14695863 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 units/day oral vitamin D(3) plus 1 g/day calcium
Number of subjects: 150
Study 14695863 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 150
Study 11573063 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 33% solution
Number of subjects: 140
Study 11573063 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 50% solution
Number of subjects: 140
Study 11573063 — intervention group
Group type: COMPARATOR
Intervention: Sucrose 33% solution
Number of subjects: 140
Study 11573063 — intervention group
Group type: COMPARATOR
Intervention: Sucrose 50% solution
Number of subjects: 140
Study 11573063 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 140
Study 11573063 — intervention group
Group type: COMPARATOR
Intervention: Glucose 5% solution
Number of subjects: 140
Study 11573063 — intervention group
Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 140
Study 9724481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) administered by continuous infusion at a dose of 10 to 40 microg/h as tolerated
Number of subjects: 18
Study 9724481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9724481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 18
Study 7503821 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase once daily
Number of subjects: 968
Study 7503821 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase twice daily
Number of subjects: 968
Study 7503821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 3057041 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 2.0 mg twice daily
Number of subjects: 155
Study 3057041 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.5 mg and 1.0 mg
Number of subjects: 155
Study 3057041 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine 4.0 mg four times daily
Number of subjects: 155
Study 3057041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 3057041 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (high-dose)
Number of subjects: 155
Study 4390958 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propranolol
Number of subjects: 8